Key result
Angiotensin II Type 1 receptor blockers were associated with lower anxiety scores in Parkinson's patients compared to ACE inhibitors or no drug (17.2 vs. 21.3 or 23.8; P=0.021).
Why the study?
The cerebral Renin-Angiotensin System might play a role in the development of anxiety and depression.
Do Angiotensin II Type 1 receptor blockers reduce anxiety and depression in newly diagnosed drug-naïve Parkinson's Disease patients compared to ACE inhibitors or no drug?
Observational (n=423)
Open-label
Do Angiotensin II Type 1 receptor blockers reduce anxiety and depression in newly diagnosed drug-naïve Parkinson's Disease patients compared to ACE inhibitors or no drug?
Absolute Event Rate: 17.2% vs 21.3%
p-value: p=0.021
ARBs may be associated with lower levels of anxiety in patients with Parkinson's Disease, warranting further investigation in randomized trials.
ARBs were associated with lower anxiety scores in PD; hypothesis-generating and requires RCTs before any clinical consideration.
BACKGROUND: The cerebral Renin-Angiotensin System might have a role in anxiety and depression development. OBJECTIVE: We explored the effects of Angiotensin II Type 1 receptor blockers (ARBs) and angiotensin-converting enzyme inhibitors (ACE-Is) on anxiety and depression in Parkinson's Disease (PD). METHODS: Four hundred and twenty-three newly diagnosed drug-naïve PD patients were evaluated using the State-Trait Anxiety Inventory (STAI) and Geriatric Depression Scale (GDS-15) tests and were monitored at baseline and for up to 3 years. RESULTS: Twelve patients were treated with ARBs and 42 with ACE-Is. ARB-treated patients had lower anxiety STAI scores than those on ACE-Is or drug-free at baseline (17.2 ± 1.3 vs. 21.3 ± 1.3, or 23.8 ± 0.5, respectively, P = 0.021) and during the follow-up (P < 0.01). Depression scores were unaffected by any of the drugs throughout the study. CONCLUSION: This small sample of ARB-treated PD patients displayed lower levels of anxiety. Randomized clinical trials are warranted.
No takes yet. Share an insight, caveat, or question.
Bordet et al. (2025) conducted an observational in Parkinson's Disease (n=423). Angiotensin II Type 1 receptor blockers (ARBs) vs. Angiotensin-converting enzyme inhibitors (ACE-Is) or drug-free was evaluated on State-Trait Anxiety Inventory (STAI) score (p=0.021). Angiotensin II Type 1 receptor blockers were associated with lower anxiety scores in Parkinson's patients compared to ACE inhibitors or no drug (17.2 vs. 21.3 or 23.8; P=0.021).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: